MESTINON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
MESTINON by Bausch + Lomb is actions: mestinon inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. First approved in 1955.
Drug data last refreshed 2m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine) is a cholinesterase inhibitor that increases acetylcholine availability at the neuromuscular junction by preventing its breakdown. It is used to treat myasthenia gravis and other neuromuscular disorders. The drug works by enhancing nerve impulse transmission across the neuromuscular junction, improving muscle strength and function.
LOE Approaching
Late-stage lifecycle product approaching loss of exclusivity signals declining team resources and transition focus toward managed care and patient retention strategies.
Mechanism of Action
ACTIONS: MESTINON inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but differs from it in certain clinically significant respects; for…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Working on MESTINON offers limited job openings (0 linked positions) and represents a mature, stable product requiring maintenance-focused commercial strategies rather than growth initiatives. Career advancement is constrained by the product's approaching loss of exclusivity and declining team headcount expectations.
Brand Manager
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.